Drug intelligence / Profile preview

SBP-304

Development stage: Unknown
Lead developer: SPARK Biopharma
Modality: Small Molecules

Overview

SBP-304 is a small molecule drug candidate developed by Sparkbiopharma. It is in the discovery phase and is being investigated for the treatment of dyslipidemias, which are disorders related to abnormal levels of lipids in the blood. The drug's primary therapeutic area is endocrinology and metabolic disease. As of now, there are no reported clinical trials or regulatory approvals for this compound, and detailed information about its mechanism of action or molecular targets has not been disclosed[1][2].

Other names: SBP-304SBP304SBP 304

Beyond the preview

Go deeper on SBP-304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-304.

Explore the full profile